{"id":"NCT02611960","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)","officialTitle":"A Two-arm, Open-label, Randomized Phase III Study of Pembrolizumab (MK-3475) Monotherapy Versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-18","primaryCompletion":"2020-11-30","completion":"2022-09-30","firstPosted":"2015-11-23","resultsPosted":"2021-12-15","lastUpdate":"2023-07-13"},"enrollment":233,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Nasopharyngeal Neoplasms"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA速"]},{"type":"DRUG","name":"Capecitabine","otherNames":["XELODA速"]},{"type":"DRUG","name":"Gemcitabine","otherNames":["GEMZAR速"]},{"type":"DRUG","name":"Docetaxel","otherNames":["TAXOTERE速"]}],"arms":[{"label":"Pembrolizumab","type":"EXPERIMENTAL"},{"label":"Standard Treatment","type":"ACTIVE_COMPARATOR"}],"summary":"This is a study of pembrolizumab (MK-3475) versus standard treatment (capecitabine, gemcitabine, or docetaxel) for the treatment of recurrent or metastatic nasopharyngeal cancer (NPC). Participants will be randomly assigned to receive either pembrolizumab or Investigator's choice of standard treatment.\n\nThe primary study hypothesis is that pembrolizumab treatment prolongs Overall Survival (OS) when compared to standard treatment.\n\nWith Amendment 7 (effective 2-March-2022), upon study completion, participants will be discontinued and may be enrolled in an extension study.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 53 months (through analysis cut-off date of 30-Nov-2020)","effectByArm":[{"arm":"Pembrolizumab","deltaMin":17.2,"sd":null},{"arm":"Standard Treatment","deltaMin":15.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2262"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":17},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["36535566"],"seeAlso":["http://merckoncologyclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":39,"n":116},"commonTop":["Cough","Fatigue","Anaemia","Pyrexia","Rash"]}}